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1. Introduction
The retina comprises diverse differentiated neurons that have specific functions. Photoreceptor
cells, the first-order neurons in the retina, have photopigments (rhodopsin and opsin) that
absorb photons. Signals produced by the photoreceptor cells are transmitted to second-order
neurons. Finally, visual signals are transmitted to the brain from the third-order neurons, the
retinal ganglion cells (RGCs). Major diseases that cause blindness in advanced countries
include glaucoma, diabetic retinopathy, retinitis pigmentosa (RP), and age-related retinop‐
athy. Loss of vision due to these diseases is irreversible. However, with regard to glaucoma,
eye drops that have the effect of reducing intraocular pressure have been developed. In diabetic
retinopathy, effective surgical treatments such as vitrectomy and photocoagulation have been
established. Blindness due to glaucoma and diabetic retinopathy can be prevented by admin‐
istering these treatments in the early phase. On the other hand, in diseases caused by gene
mutations, such as RP, effective treatments for delaying photoreceptor degeneration have not
yet been established. Degeneration of photoreceptor cells results in loss of vision, even if other
retinal neurons are intact [1-3].
RP is a disease that causes blindness due to photoreceptor degeneration. Symptoms include
night blindness and loss of peripheral and central vision. Approximately 1 in 4,000 people are
affected by this disease [4]. In 1990, Dryja et al. [5] first identified a point mutation in the rhodopsin
gene from RP patients. A number of gene mutations responsible for RP has subsequently been
identified. Most of these genes are associated with the phototransduction pathway in the retina.
In some cases, the mutated gene exists not only in photoreceptor cells but also in retinal pigment
epithelial cells. To date, 53 causative genes and 7 loci of RP have been identified (http://
www.sph.uth.tmc.edu/Retnet/). Leber’s congenital amaurosis (LCA) is another retinal degener‐
ative disease predicted to affect approximately 1/81000 individuals [6]. Most LCA patients have
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severe visual defects in childhood. Histological analysis of the retinas of LCA patients shows
marked retinal atrophy in the outer retinal layer, vascular thickening and sclerosis, and atrophy
of the retinal pigment epithelium (RPE) [7]. Leber classified the disease as a type of RP on the
basis of these characteristics. Later, Franceschetti and Dieterle differentiated it from retinal
dystrophy based on the features of electroretinograms (ERGs) in these patients. Many gene
mutations involved in LCA have been identified and the disease has been classified into 15
subtypes based on the affected gene [8-13]. Among these, LCA2, accounting for 10% of LCA
cases [14], is due to a mutation in the RPE65 gene, which encodes all-trans retinyl ester isomer‐
ase. Deficiency in RPE65, leads to severe loss of visual function. Thus, in the case of LCA2, the
cause of the disease is clearly identified as the biochemical blockade of the visual cycle caused
by RPE65 deficiency [11,12]. Replacement therapy using the RPE65 gene is a candidate therapeu‐
tic strategy for LCA2. Indeed, successful results have been reported in RPE65 replacement
therapy with the LCA2 animal model, Briard dogs [15]. After proof-of-principle studies [16],
phase I trials using adeno-associated virus vector type 2 were conducted in 3 independent groups
[17]. The results showed no adverse effects such as systemic dissemination of vector or immuno‐
logical responses to the vector or transgene. Importantly, improvement of visual function as
evaluated by microperimetry was observed in 1 subject [18,19]. Two other groups also report‐
ed improvement in visual function [20,21]. Continuous follow-ups for 1.5 years [22] have
confirmed the safety and tolerability of replacement gene therapy [23]. The various hereditary
forms of RP are as follows: autosomal dominant, recessive, and X-linked recessive. The Pro23 -
> His gene mutation in the rhodopsin gene [24,25] occurs in 20–30% of all RP patients in Europe
and the U.S. In contrast, the occurrence in Japan is only a few percent. Thus, in addition to the
diversity of the gene mutations, their frequencies vary characteristically among different races.
Differences in the progression, clinical findings, and development of the disease are also observed
among different patients, even in those with the same mutation. A common feature of photore‐
ceptor cell death caused by various gene mutations is eventual apoptosis via a common pathway
[26]. Based on this rationale, various kinds of methods to prevent apoptosis, such as chemical
treatment [27,28] and gene therapy, including gene replacement and neurotrophic factor
supplementation [29-31], have been investigated. However, these strategies have not been
successful in the complete prevention of cell death, although they have been shown to delay
degeneration. The diversity of clinical features and gene mutations makes it difficult to develop
effective treatments for RP.
A retinal prosthesis, comprising electrodes, an image processor, and a camera, is the only
method to restore vision that has been studied [32-36]. Recently, a new strategy involving gene
therapy for restoring vision has been developed using bacteriorhodopsin family genes [37,38].
The channelrhodopsin-2 (ChR2) gene derived from the green alga Chlamydomonas functions
as a photoreceptor and cation-selective channel [39]. After the absorption of photons by
photopigments, photon acquisition is completed by a chain reaction involving certain photo‐
receptor-specific proteins. Thus, the phototransduction pathway in photoreceptor cells
requires not only photopigments but also certain photoreceptor-specific proteins, which
complicates the reaction. Due to the inherent characteristics of ChR2, photosensitive neurons
can be produced by the transfer of the ChR2 gene into neurons [40-42]. Here, we introduce
new strategies for restoring vision by using channelrhodopsins.
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2. Materials and methods
All the experiments performed for this report were approved by the Tohoku University
Animal Care Committee, which is accredited by the Ministry of Education, Culture, Sports,
Science, and Technology of Japan. Every effort was made to minimize the number and
suffering of animals used in the following experiments.
Animals
We used 2 types of photoreceptor degeneration models: a genetically blind rat model and a
light-induced photoreceptor degeneration model. The experimental design for each of these
models is shown in Fig. 1.
Figure 1. Experimental design. Two types of photoreceptor degeneration models were used in this study. The photo‐
receptor cells of RCS rats degenerate by 3 months after birth due to the Mertk gene mutation. On the other hand,
Thy-TG rats have native photoreceptors. Therefore, we subjected TG rats to continuous light exposure to induce pho‐
toreceptor degeneration. To confirm photoreceptor degeneration, ERGs were recorded before performing behavioral
assessments. Finally, the eyes from all animals were subjected to histological examination.
Genetically blind rats
Royal College of Surgeons (RCS; rdy/rdy) rats [43,44] were used as model animals for photorecep‐
tor degeneration in our experiments. The RCS rat, an animal model of recessively inherited retinal
degeneration, is widely used in the study of photoreceptor degeneration. The gene responsible
is the receptor tyrosine kinase gene Mertk [45], and mutations in MERTK, the human ortholog of
the RCS rat retinal dystrophy gene, cause RP [46]. Photoreceptor degeneration is almost complete
by 3 months after birth. We intravitreously injected the AAV-ChR2V vector into 6-month- or 10-
month-old RCS rats. The rats were obtained from CLEA Japan, Inc. (Tokyo, Japan).
Thy-I ChR2 transgenic rats
We established transgenic (TG) rats harboring the ChR2 gene regulated by the Thy-1.2
promoter to investigate contrast sensitivity at each spatial frequency [47]. The rat Thy-1.2
antigen has been found to be abundant in the brain and thymus [48,49]. In the retina, the
Thy-1.2 antigen is recognized as a marker specific to RGCs [50,51]. It is necessary to induce the
degeneration of native photoreceptor cells in order to investigate the visual function conferred
by ChR2-expressing RGCs, because the Thy-I TG rat has native photoreceptor cells. For this
purpose, Thy-I TG rats were subjected to light-induced photoreceptor degeneration. Briefly,
Thy-I TG rats were kept in cyclic light (12 hours ON/OFF: 5–10 lux/dark) for at least 2 weeks
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prior to light exposure. The rats were then exposed to a 3000-lux intensity of fluorescent light
for 7 days [28]. We used a light exposure box (NK Systems, Tokyo, Japan) to control the timing
and light intensity for the induction of photoreceptor degeneration. After induction, we
recorded ERGs to confirm photoreceptor degeneration.
Preparation of the adeno-associated virus vector
The adeno-associated virus (AAV) vector with the ChR2 gene was constructed as described
previously [38]. Following this, the AAV Helper-Free System (Stratagene, La Jolla, CA) was
used to produce infectious AAV-Venus (control) and AAV-ChR2V virions, which were
purified by a single-step column purification method as previously described [52].
Recording of ERGs and visual electrophysiology (VEP)
ERGs and VEP readings were recorded using a Neuropack (MEB-9102; Nihon Kohden, Tokyo,
Japan) according to methods previously described [38,53]. Briefly, rats were dark-adapted
overnight, and the pupils were dilated with 1% atropine and 2.5% phenylephrine hydrochlor‐
ide. Small contact lenses with gold wire loops were placed on both corneas, and a silver wire
reference electrode was inserted subcutaneously between the eyes. Eyes were stimulated with
flash light stimuli of 10-ms duration using a blue LED. Full-field scotopic ERGs were recorded,
band-pass filtered at 0.3–500 Hz, and averaged for 5 responses at each light intensity. For VEP
recordings, recording electrodes (silver-silver chloride) were placed epidurally on each side,
7 mm behind the bregma and 3 mm lateral of the midline, and a reference electrode was placed
epidurally on the midline 12 mm behind the bregma, at least 7 days before the experiments
[54,55]. Under ketamine-xylazine anesthesia, the pupils were dilated with 1% atropine and
2.5% phenylephrine hydrochloride. The ground electrode clip was placed on the tail. Photic
stimuli of 20-ms duration were generated under various intensities by pulse activation of a
blue LED. The high- and low-pass filters were set to 50 kHz and 0.05 kHz, respectively. One
hundred consecutive response waveforms were averaged for each VEP measurement.
Determination of transduction efficiency
At the end of the experiment, RCS and Thy-TG rats were sacrificed, and their eyes were
resected and fixed in 4% paraformaldehyde and 0.1 M phosphate buffer, pH 7.4 [56]. The eye
of each rat was flat-mounted on a slide and covered with Vectashield medium (Vector
Laboratories, Burlingame, CA) to prevent the degradation of fluorescence. Then, the number
of positive cells was counted.
3. Behavioral assessment
The spatial vision of each animal was quantified by its optomotor response. We used a virtual
optomotor system to evaluate the contrast sensitivities of each spatial frequency. The original
virtual optomotor system described by Prusky et al. [57] was modified for rats [47]. When a
drum is rotated around an animal with printed visual stimuli on the inside wall, the animal
tracks the stimulus by turning its head. A light-dark grating pattern was displayed on
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computer monitors (ProLite E1902WS; Iiyama, Tokyo, Japan) arranged in a square around a
platform. The software controlled the speed of virtual optomotor rotation, which was set at 12
degrees per second (2 rpm) in all experiments. The spatial frequency and the contrast of the
grating pattern were varied but the average brightness was kept constant.
The animal was allowed to move freely on the platform in the virtual optomotor system. The
grating session was started at a low spatial frequency (0.06 cycles/degree) with maximal
contrast. An experimenter assessed whether the animals tracked the rotation, by monitoring
the head movement and the presented rotating stimulus simultaneously on another display
connected to the video camera. If head movement simultaneous with the rotation was evident,
the experimenter judged that the animal could discriminate the grating, and proceeded to the
next grating session. If the movement was ambiguous, the same grating session was presented
again. All behavioral tests were double-blinded and performed during the first few hours of
the animals’ light cycle (light on at 8 AM).
4. Results
4.1. Recording of VEP measurements in RCS rats
VEP measurements in 6- or 10-month-old RCS rats are expected to be abolished due to loss of
photoreceptor cells. Generally, in RCS rats, photoreceptor degeneration is almost complete by
3 months after birth. Indeed, VEP measurements were not evoked even by the maximal LED
flash in any of the aged RCS (rdy/rdy) rats (Fig. 2A). On the other hand, robust VEPs were
evoked by the blue LED flash in RCS rats injected with the AAV-ChR2V vector (Fig. 2A).
Initially, small VEP responses were observed at 2 weeks after AAV injection (data not shown),
and the maximum amplitudes of VEP were observed 8 weeks later [58]. There were notable
differences in sample waveforms from 6- and 10-month-old rats injected with AAV-ChR2V.
Amplitudes and latencies of VEPs from 6-month-old rats were larger and shorter, respectively,
than those from 10-month-old rats (Fig. 2B).
4.2. Transduction efficiencies of ChR2 in retinas of RCS rats
The expression of the ChR2 gene was evaluated by measuring Venus fluorescence in RCS rat
retinas (Fig. 3A). The number of positive cells in rats injected at 10 months of age was signifi‐
cantly less than that injected at 6 months of age (Fig. 3B). The number of RGCs decreased
linearly with age, following photoreceptor degeneration in the RCS rats (Fig. 3C). We have
previously shown [56] that the ChR2 gene is mainly expressed in RGCs upon intravitreous
injection of the AAV-ChR2V vector. Therefore, the observed decrease in the number of RGCs
with age suggests that the transduction efficiencies at both ages are very similar.
4.3. Photoreceptor degeneration in Thy-I TG rats
There were 11–12 rows of photoreceptor nuclei in the outer nuclear layer (ONL) of the Thy-1
TG rats; this is a number usually observed in rodents without retinal degeneration [59].
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Following continuous light exposure, photoreceptor cells disappeared (Fig. 4A). ERGs showed
no response, indicating that the photoreceptor cells degenerated in the whole retina (Fig. 4B).
Figure 2. VEP recordings before and after the injection of AAV-ChR2V. (A) VEP recordings from both 6-month- and
10-month-old RCS rats showed no responses. However, VEPs responses were clearly elicited 8 weeks after injection.
(B) The amplitudes and latencies from rats injected with AAV-ChR2 at 6 months of age (n = 8) were significantly larger
and shorter than those injected at 10 months of age (n = 4).
Figure 3. Transduction efficiencies of ChR2 in retinas of RCS rats. (A) Retinal whole-mount specimens obtained from
rats injected with AAV-ChR2 at 6 and 10 months of age. (B) Venus-positive cells expressing the ChR2 gene were ob‐
served in whole-mount specimens. (C) The number of RGCs decreased with age.
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However, robust VEP measurements could be recorded, even though the photoreceptor cells
had completely degenerated (Fig. 4B). Intense expression of the ChR2 gene was observed in
the entire retina, with about 45% of RGCs positive for ChR2 (Fig. 4C).
Figure 4. Electrophysiological response of Thy-I TG rats after photoreceptor degeneration. (A) Hematoxylin-eosin
staining of the retina showed the degeneration of the native photoreceptor cells after continuous light exposure. (B)
Extensive expression of the ChR2 gene was observed throughout the retina. (C) The ERG response was completely
abolished following continuous light exposure, indicating that native photoreceptor cells had degenerated through‐
out the retina. VEP measurements could still be recorded after photoreceptor degeneration.
4.4. Behavioral assessment in photoreceptor degenerated-Thy-I TG rat
In our virtual optomotor system, a stimulus of blue stripes over a black background was
produced according to a sine wave function with variable amplitude and frequency (Fig.
5A). All the photoreceptor-degenerated Thy-I TG and wild-type (normal) rats tracked the
virtual rotating blue/black gratings (Fig. 5B). However, tracking stopped when the contrast
was reduced below a specific threshold. We observed that contrast sensitivity was small at the
minimal spatial frequency of 0.06 cycles per degree (CPD), increased with an increase in spatial
frequency, and was negligible at spatial frequencies over 0.52 CPD. Therefore, the relationship
followed an inverted U-shaped curve, as noted in previous reports [57]. In photoreceptor-
degenerated Thy-I TG rats, no reduction of contrast sensitivity was observed at any spatial
frequency. Unexpectedly, the contrast sensitivity was instead somewhat enhanced at low
spatial frequencies such as 0.09 or 0.18 CPD (Fig. 5C).
5. Discussion
The photo-acquisition system of mammalian photoreceptor cells, which mediates various
photoreceptor-specific proteins, is very complicated. In contrast, the corresponding system in
green algae such as Chlamydomonas and Volvox is simpler. ChR2 contains a 13-cis retinal that
absorbs a photon, inducing a conformational change. The ChR2 functions as a cation-selective
ion channel. For this reason, the transfer of a single gene, ChR2, to RGCs allows the generation
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of photosensitive RGCs. In the normal visual pathway, the light incident upon the eyes is first
received by photoreceptor cells located at the end of the retinal layers. The photoreceptor cells
control neurotransmitter release, and second-order neurons located in the inner nuclear layer
respond to the neurotransmitter. Finally, RGCs produce action potentials and transmit to the
lateral geniculate nucleus (LGN) via the optic nerve (Fig. 6). In RP, the photo-acquisition
system is damaged due to the degeneration of photoreceptor cells, even if the other retinal
layers remain intact. RGCs that are rendered photosensitive by the transfer of the ChR2 gene
can directly respond to light and transmit signals to the brain. In this newly organized photo-
acquisition system, the other retinal neurons besides the RGCs are not required for the
perception of light.
Although VEP responses recovered after ChR2 gene transfer, the amplitudes and waveforms
were different between rats injected with AAV-ChR2V at 6 and 10 months of age. One
possibility is that RGC activity decayed after photoreceptor degeneration. However, our data
show that the number of RGCs decreased after photoreceptor degeneration (Fig. 3C). The
calculated RGC transduction efficiencies in 6-month-old rats were the same as those in 10-
month-old rats. The differences in the recorded amplitudes and latencies shown in Fig. 2
appear to be due to differences in the number of photosensitive RGCs. We previously reported
that the RGC transduction efficiency in 10-month-old rats was about 28% [38]. Subsequently,
Isago et al. showed that the RGC transduction efficiencies in 6- and 10-month-old rats were
28.3 and 27.7%, respectively [56]. The data clearly indicates that the transduction efficiency is
the same, although the number of ChR2-expressing cells was lower, corresponding to the
decrease in the number of RGCs.
Figure 5. Behavioral assessment using a digital optomotor. (A) The digital optomotor consisted of 4 displays sur‐
rounding a platform. The number of stripes and the contrast were controlled by software. (B) Superimposed images
from movies showed that the rats were able to discriminate the moving stripes. The arrow indicates the direction of
the moving stripes. The asterisk indicates the point of the rat’s nose. (C) The contrast sensitivities of photoreceptor-
degenerated Thy-I TG rats were higher at low spatial frequencies compared to those of wild-type (normal) rats (n = 8).
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To investigate visual acuity resulting from ChR2-expressing RGCs, we established a TG rat
model expressing the ChR2 gene in RGCs. Photoreceptor-degenerated TG rats clearly tracked
the rotation of blue-black stripes in a virtual optomotor. However, RCS rats that received the
ChR2 gene in the AAV vector did not track the rotation of the virtual optomotor at any spatial
frequency. Recently, we tested the behavior of RCS rats using a mechanical optomotor system
and showed that the intensity of luminosity the rat received was the most important factor
influencing their tracking of the rotation of the column [53]. A luminosity of over 500 lux
was needed to induce head tracking in ChR2-expressing RCS rats. However, the maximum
luminosity of the virtual optomotor was about 100 lux. It was therefore too low to induce
head tracking in RCS rats. The question then arises: what is the difference between the TG
and RCS rats? We do not have a reasonable explanation for this. One possibility is that the
number of ChR2-expressing RGCs in the TG rat is greater than that in the RCS rat. About
45% of the RGCs expressed ChR2 in the TG rat. Compared to the TG rat, the transduction
efficiency in the RCS rat is about 28% independent of the age of the animal. This may affect
the light sensitivity. As the another explanation, in the case of TG rats, ChR2 is expressed
after birth; therefore, there is a possibility that retinal organization and function might be
altered, that cannot be ruled out.
RGCs are merely one of the candidate cell types that could receive the ChR2 gene. Lagali et al.
[60] succeeded in transferring the ChR2 gene into ON-bipolar cells in the retina and confirmed
the restoration of visual and behavioral responses. ON- and OFF-bipolar cells receive synaptic
input from photoreceptors. Considering that ChR2 can elicit light-on responses, ON-bipolar
cells seem to be the most appropriate cells for the transfer of the ChR2 gene. However, 2
questions arise in this regard. First, how can we deliver the ChR2 gene into ON-bipolar cells
for human gene therapy? Lagali et al. [60] transferred the ChR2 gene into neonatal mice by
electroporation of the plasmid vector. It is generally difficult to transfer a gene into the depths
Figure 6. Summary of the visual pathway in ChR2-expressing RGCs. In the normal visual pathway, light (visual signals)
is received by photoreceptor cells located at the end of the retinal layer. Photoreceptor cells produce signals that are
transmitted to the inner nuclear layer. Finally, RGCs generate action potentials and thereby transmit signals to the
LGN. RGCs play a role in transferring the visual signal to the brain. On the other hand, ChR2-expressing retinal gan‐
glion cells directly receive light, produce action potentials, and transmit them to the LGN. Therefore, there is no need
for mediation by other retinal cells.
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of the retina via intravitreous injection of AAV vectors, in spite of the development of various
serotypes of AAV vectors for retinal gene therapy [61-65]. Second, does synaptic transmission
remain intact after photoreceptor degeneration? Some studies have reported that retinal
remodeling is triggered in bipolar cells and horizontal cells following photoreceptor degen‐
eration [66-70]. Recently, Doroudchi et al. [71] succeeded in transferring the ChR2 gene into
ON-bipolar cells by the subretinal injection of a modified AAV vector (AAV8-Y733F) [72] that
included a specific promoter for ON-bipolar cells (mGRM6-SV40), and demonstrated the
behavioral recovery of the light response. These 2 questions could be resolved by these
attractive methods used the specific promoter and the modified AAV vectors if the recovered
visual acuity is investigated using a behavioral approach.
Since the discovery of ChR2, bacteriorhodopsins that have similar functions as that of ChR2
derived from Chlamydomonas have been identified. Channelrhodopsin-1 from the green alga
Volvox [73] is a light-activated cation channel that has a different wavelength sensitivity from
that of Chlamydomonas-derived ChR2. Halorhodopsin, which functions as a light-activated
chloride channel, has been identified in Halobacterium salinarum [74,75]. Researchers have
attempted to discover new light-activated ion channel genes, or to artificially design more
functional ones [76-78]. In the future, more effective gene therapy strategies for restoring vision
in RP might be developed using newly developed genes and vectors.
6. Conclusion
Target diseases for gene therapy were previously restricted to lethal and severe diseases that
lead to death. In our country (Japan), the gene therapy guidelines were updated in 2002,
whereby diseases in which bodily functions are severely impaired, such as loss of arms or legs,
blindness, and deafness, were added to the list of target diseases for gene therapy. Based on
these guidelines, people suffering from impaired vision caused by RP are eligible for gene
therapy. However, gene therapy using genes derived from living organisms other than
humans has not previously been tested in clinical trials. Safety studies, especially immuno‐
logical reactions, using appropriate animal models in ChR2-based gene therapy is important
before proceeding to clinical trials.
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